Posted On: 12/07/2016 10:10:01 AM
Post# of 72447
It's all over the place on Scottrade...
Latest News Headlines for Cellceutix Corp
Cellceutix Phase 2 Trial Dose Escalates in 2nd Cohort for Brilacidin as a Novel Anti-Inflammatory Drug Candidate for Ulcerative Colitis *
Wednesday 12/07/2016 07:31 AM ET - Dow Jones News
Cellceutix Phase 2 Trial Dose Escalates in 2nd -2-
Wednesday 12/07/2016 07:30 AM ET - GlobeNewsWire via Dow Jones News
included in Cellceutix's filings with the Securities and Exchange Commission. You should not place undue reliance on any forward-looking statements. Cellceutix undertakes no obligation to release publicly the results of any revisions to any such forward-looking statements that may be made to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events, except as required by applicable law or regulation.
Cellceutix Phase 2 Trial Dose Escalates in 2nd Cohort for Brilacidin as a Novel Anti-Inflammatory Drug Candidate for Ulcerative Colitis
Wednesday 12/07/2016 07:30 AM ET - GlobeNewsWire via Dow Jones News
Cellceutix Phase 2 Trial Dose Escalates in 2nd Cohort for Brilacidin as a Novel Anti-Inflammatory Drug Candidate for Ulcerative Colitis BEVERLY, Mass., Dec. 07, 2016 (GLOBE NEWSWIRE) -- Cellceutix Corporation, (OTCQB:CTIX) ("the Company"
, a clinical stage biopharmaceutical company developing innovative therapies with dermatology, oncology, anti-inflammatory, and antibiotic applications, is pleased to announce today initiation of the second cohort of patients treated with Brilacidin for Ulcerative Proctitis/Ulcerative Proctosigmoiditis (UP/UPS), two types of Inflammatory Bowel Disease (IBD).
View more recent headlines
Cheers Kelt, always good to see you.
Latest News Headlines for Cellceutix Corp
Cellceutix Phase 2 Trial Dose Escalates in 2nd Cohort for Brilacidin as a Novel Anti-Inflammatory Drug Candidate for Ulcerative Colitis *
Wednesday 12/07/2016 07:31 AM ET - Dow Jones News
Cellceutix Phase 2 Trial Dose Escalates in 2nd -2-
Wednesday 12/07/2016 07:30 AM ET - GlobeNewsWire via Dow Jones News
included in Cellceutix's filings with the Securities and Exchange Commission. You should not place undue reliance on any forward-looking statements. Cellceutix undertakes no obligation to release publicly the results of any revisions to any such forward-looking statements that may be made to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events, except as required by applicable law or regulation.
Cellceutix Phase 2 Trial Dose Escalates in 2nd Cohort for Brilacidin as a Novel Anti-Inflammatory Drug Candidate for Ulcerative Colitis
Wednesday 12/07/2016 07:30 AM ET - GlobeNewsWire via Dow Jones News
Cellceutix Phase 2 Trial Dose Escalates in 2nd Cohort for Brilacidin as a Novel Anti-Inflammatory Drug Candidate for Ulcerative Colitis BEVERLY, Mass., Dec. 07, 2016 (GLOBE NEWSWIRE) -- Cellceutix Corporation, (OTCQB:CTIX) ("the Company"
, a clinical stage biopharmaceutical company developing innovative therapies with dermatology, oncology, anti-inflammatory, and antibiotic applications, is pleased to announce today initiation of the second cohort of patients treated with Brilacidin for Ulcerative Proctitis/Ulcerative Proctosigmoiditis (UP/UPS), two types of Inflammatory Bowel Disease (IBD). View more recent headlines
Cheers Kelt, always good to see you.
(1)
(0)
